AI company raises $3m to develop antibodies targeting GPCRs
Drug Discovery World
MARCH 1, 2023
Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function.
Let's personalize your content